Trending...
- Strategic Talent Associates Launches THE ALIGNED RESET™
- Virginia Moving Company Nearly Doubles Customer Calls in Two Weeks After Switching to CARL — the Bold New Alternative to WordPress
- Why Athletic Recovery Begins in the Nervous System
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased CareDx, Inc. ("CareDx" or the "Company") (NASDAQ: CDNA) common stock between February 24, 2021 and May 5, 2022, inclusive (the "Class Period"). CareDx investors have until July 22, 2022 to file a lead plaintiff motion.
Investors suffering losses on their CareDx investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
On October 28, 2021, after the market closed, CareDx revealed that it had received a civil investigative demand from the U.S. Department of Justice as part of an investigation into the Company's "business practices related to [its] kidney testing and phlebotomy services." The Company had also received a subpoena from the U.S. Securities and Exchange Commission ("SEC") for similar issues as well as certain accounting and public reporting practices.
On this news, the Company's share price fell $19.34, or 27%, to close at $51.00 per share on October 29, 2021, thereby injuring investors.
More on The PennZone
Then, on April 15, 2022, the Company's former Head of Community Nephrology filed a complaint that provided detail regarding CareDx's misconduct, including the use of its home-based blood-drawing service, RemoTraC to improperly bundle the Company's most expensive testing services with other blood tests, that led to the government investigations, as well as the Company's knowledge of the misconduct and its attempts to conceal it.
On this news, CareDx's stock fell $2.89, or 8.1%, to close at $32.55 on April 18, 2022, thereby injuring investors further.
Then, on May 5, 2022, after the market closed, the Company released its financial results for the first quarter of 2022, reporting that testing service revenue fell short of analysts' expectations with an average price decline of 4.9%.
On this news, CareDx's stock fell $5.88, or 18.6%, to close at $25.78 on May 6, 2022, thereby injuring investors further.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) CareDx had engaged in a variety of improper and illegal schemes to inflate testing services revenue and demand, including pushing a surveillance protocol through inaccurate marketing materials, offering extravagant inducements or kickbacks to physicians and other providers, and improperly bundling expensive testing services with other blood tests as part of the RemoTraC service; (2) these practices, and others, subjected CareDx to an undisclosed risk of regulatory scrutiny; (3) these practices rendered the Company's testing services revenue reported throughout the Class Period artificially inflated; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
More on The PennZone
If you purchased CareDx common stock, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
Investors suffering losses on their CareDx investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
On October 28, 2021, after the market closed, CareDx revealed that it had received a civil investigative demand from the U.S. Department of Justice as part of an investigation into the Company's "business practices related to [its] kidney testing and phlebotomy services." The Company had also received a subpoena from the U.S. Securities and Exchange Commission ("SEC") for similar issues as well as certain accounting and public reporting practices.
On this news, the Company's share price fell $19.34, or 27%, to close at $51.00 per share on October 29, 2021, thereby injuring investors.
More on The PennZone
- Best Companies Group Launches Free Best Banks to Work For Program
- I Voted Tvocracy and I Voted Radiocracy
- Tolle Lege Learning Launches Publishing House to Revolutionize Early Learning Initiatives
- HRC Fertility Celebrates Beverly Hills Grand Opening, Spotlighting Fertility Care as Women's Health Month Begins
- HRC Fertility's Dr. Christo G. Zouves Appointed to San Mateo County Medical Association Board of Directors
Then, on April 15, 2022, the Company's former Head of Community Nephrology filed a complaint that provided detail regarding CareDx's misconduct, including the use of its home-based blood-drawing service, RemoTraC to improperly bundle the Company's most expensive testing services with other blood tests, that led to the government investigations, as well as the Company's knowledge of the misconduct and its attempts to conceal it.
On this news, CareDx's stock fell $2.89, or 8.1%, to close at $32.55 on April 18, 2022, thereby injuring investors further.
Then, on May 5, 2022, after the market closed, the Company released its financial results for the first quarter of 2022, reporting that testing service revenue fell short of analysts' expectations with an average price decline of 4.9%.
On this news, CareDx's stock fell $5.88, or 18.6%, to close at $25.78 on May 6, 2022, thereby injuring investors further.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) CareDx had engaged in a variety of improper and illegal schemes to inflate testing services revenue and demand, including pushing a surveillance protocol through inaccurate marketing materials, offering extravagant inducements or kickbacks to physicians and other providers, and improperly bundling expensive testing services with other blood tests as part of the RemoTraC service; (2) these practices, and others, subjected CareDx to an undisclosed risk of regulatory scrutiny; (3) these practices rendered the Company's testing services revenue reported throughout the Class Period artificially inflated; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
More on The PennZone
- HealthBook+ and Stonebrook Risk Solutions Partner to Bring Predictive Intelligence to Healthcare Risk
- Umbrella Becomes First FinOps Platform to Support AWS Billing Transfer Onboarding
- RECYCLEXPERT FZE Strengthens Leadership in Data Destruction UAE and GCC with Certified Secure ITAD Services
- Plasma-Activated Nitric Oxide Cream Outperforms L-Arginine Skincare - New Research Explains Why
- Assymetrix Launches the Deepest Independent Prediction Market Data API
If you purchased CareDx common stock, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
Filed Under: Business
0 Comments
Latest on The PennZone
- Michael H. Kaplan, Colorado Workers' Compensation Attorney, Rallies Athlete Unions Against Proposed Legislative "Carve-Outs"
- Viasat, Galaxy 1 Communications and L2 Aviation to bring avionics integration to Advanced Air Mobility
- W&W Residential Services Celebrates National Skilled Trades Day
- Fulton County DA Fani Willis Officially Endorses Dr. Heavenly Kimes + Black Economic Agenda
- Bellwether Farm Presents Kerry Hill Lamb to His Majesty King Charles III During Historic U.S. State Visit
- Mr. T, Dafne Keen, Ron Perlman, Nick Apostolides, Angela Sant'Albano to FAN EXPO Philadelphia
- New Study Finds Americans Judge Vacations on Value, Not Price — Signaling a Permanent Shift in How Travel Gets Booked
- Pomona Organic Launches New Website, Surpasses 10 Million Bottles Sold, and Opens Affiliate Program to Creators
- Postmortem Pathology Opens Sacramento Office Offering Private Autopsies for Families and Healthcare Investigations
- Postmortem Pathology, a leading provider of private autopsies, has announced its expansion into the Las Vegas market
- Kick'em Out Quick® Evictions Announces a New Endorsed Eviction Attorney in Atlanta / Fulton County, GA
- Why Athletic Recovery Begins in the Nervous System
- A Hidden Magical World Awaits in Ashley Gayheart's Upcoming Young Adult Fantasy, Rosewood Academy: The Awakening
- Scott Ritsema of Bisnar Chase Selected for 2026 National Traumatic Brain Injury Association
- Flint Youth Film Festival Shifts Gears, Becomes Vehicle City Film Festival
- 62% of Gen X have no estate planning documents — Trust & Will research identifies "the Sandwich Gap"
- Nayarit's Jungle Coast Redefines Luxury Travel on Mexico's Pacific Now More Accessible Than Ever
- $10 Million Annual Revenue Merger, Profitable Partner in AI Powered Specialty Automotive Sales Projected to Scale Above $200M: Stock Symbol: NWPG
- Virginia Moving Company Nearly Doubles Customer Calls in Two Weeks After Switching to CARL — the Bold New Alternative to WordPress
- JR AIR TOOLS Launches Factory-Direct Air Hydraulic Jacks for Semi Trucks & Commercial Fleets